11 results about "Omeprazole" patented technology

This invention discloses an omeprazole enteric-coated composition, which is prepared by hot melt extrusion of omeprazole, a solid lipid carrier, a surfactant, a pH-sensitive polymer, and a plasticizer to form a biphase matrix structure with the pH-sensitive polymer as the continuous phase and the omeprazole-containing lipid phase as the dispersed phase. The preparation method is also disclosed, thereby achieving gastric protection of omeprazole, rapid intestinal release, and good storage stability.

The invention provides an omeprazole enteric capsule and a preparation method thereof, and belongs to the technical field of medicines. The omeprazole enteric-coated capsule is prepared by taking an omeprazole derivative as an active component and embedding the omeprazole derivative through a sustained-release enteric-coated material. According to the omeprazole enteric capsule prepared by the invention, by adjusting the molecular structure of omeprazole, the water solubility and the bioavailability of omeprazole are improved, the half-life period is prolonged, and by embedding the sustained-release enteric material, the targeted slow release of intestinal tracts is realized, so that the drug effect time is prolonged, the problem of repeated medication is avoided, the compliance of patients is improved, and the bioavailability of the omeprazole enteric capsule is improved. Wide application prospects are realized.

This invention provides a quetiapine fumarate tablet composition and its preparation method. The composition contains the following components: quetiapine fumarate-hydroxypropyl-β-cyclodextrin co-treated product, povidone, calcium hydrogen phosphate, microcrystalline cellulose, sodium carboxymethyl starch, lactose monohydrate, magnesium stearate, and omeprazole. This invention also provides a method for processing a large-particle-size, highly fluid, highly soluble, and stable active pharmaceutical ingredient (API). This involves adding the API to a hydroxypropyl-β-cyclodextrin solution, homogenizing the resulting suspension, and spray-drying to prepare the quetiapine fumarate-hydroxypropyl-β-cyclodextrin co-treated product. The resulting intermediate powder obtained by wet granulation of the above-mentioned API-containing product exhibits superior flowability, smaller relative standard deviation of content uniformity, and a faster tableting rate after compression compared to tablets prepared solely from large-particle-size APIs, which is highly beneficial for industrial-scale production.

The present invention relates to a coated tablet composition comprising omeprazole (KN510) with improved stability and a method for preparing the same. More specifically, the present invention relates to a bilayer coated tablet composition comprising omeprazole, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, and a method for preparing the same. In the present invention, in order to increase the stability of a KN510 tablet (30 mg) comprising omeprazole, a tablet composition is designed using calcium carbonate. It is proved that when mannitol and lactose are contained as excipients, tablets satisfying disintegration, dissolution and friability standards can be prepared, and the increase of related substances is significantly reduced.

This invention discloses an esomeprazole sodium and its purification method, relating to the field of drug synthesis technology. The purification method includes the following steps: S1, mechanically grinding crude esomeprazole sodium with a composite solid purification additive to obtain an activated mixture; the composite solid purification additive is a composition of diisopropyl tartrate and hydroxypropyl-β-cyclodextrin, and the mass ratio of diisopropyl tartrate to hydroxypropyl-β-cyclodextrin is (1~5):(2~4); S2, adding a washing solvent to the activated mixture and stirring and washing, then performing solid-liquid separation to obtain a solid wet product; the washing solvent includes ethyl acetate, methyl tert-butyl ether, or isopropyl ether; S3, drying the solid wet product to obtain purified esomeprazole sodium. This purification method is not only simple in process and has a high product yield, but also does not introduce new impurities, and the product has high optical and chemical purity.

This invention discloses a gelling material for treating gastric diseases and its preparation method, belonging to the field of pharmaceutical preparation technology. The gelling material is composed of 8-10g of Codonopsis pilosula extract, 6-10g of Bletilla striata extract, 6-8g of Dioscorea opposita extract, 2-4g of Citrus reticulata peel extract, 2-3g of gelatin, 2-4g of xylitol, 0.1-0.2g of citric acid, and 60.8-73.9g of purified water. As a carrier matrix, the gelling material of this invention exhibits good compatibility with commonly used antacids (such as calcium carbonate), PPIs (such as omeprazole), antibiotics (such as amoxicillin and clarithromycin), and traditional Chinese medicine extracts. During preparation, the above-mentioned active pharmaceutical ingredients (APIs) can be uniformly dispersed in the gel matrix, achieving integrated synergistic treatment of "mucosal protection + acid suppression / bactericidal action" without compromising their chemical stability or causing burst release problems, providing an ideal platform for developing compound gastric disease preparations.

The application provides a compound omeprazole dry suspension and a preparation method thereof, and relates to the technical field of pharmaceutical preparations.The compound omeprazole dry suspension comprises the following raw materials: omeprazole, sodium bicarbonate, magnesium silico-aluminate, hard stearic acid modified hydrotalcite, low acyl gellan gum, hydroxypropyl methyl cellulose and trehalose.The application provides a compound omeprazole dry suspension and a preparation method thereof, and the compound omeprazole dry suspension with specific particle size is prepared through specific proportioning of auxiliary materials and a specific preparation process, and the stability and solubility are significantly improved.

An omeprazole delayed release tablet comprises a core and an enteric coating over the core. The core consists essentially of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate. The enteric coating over the core consists essentially of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, and less than 500 ppm of residual ammonium hydroxide.

The invention relates to an escomeprazole enteric capsule as well as a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. The enteric capsule comprises an escomeprazole magnesium enteric pellet, the enteric pellet sequentially comprises a blank pellet core, an upper drug layer, an isolation layer and an enteric layer from inside to outside, the upper drug layer comprises escomeprazole and tris (hydroxymethyl) aminomethane, and the weight ratio of escomeprazole to tris (hydroxymethyl) aminomethane is 1: (0.01-0.03).

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

A method of treating patients who are positive for Helicobacter pylori infection comprises determining that a first patient who is positive for Helicobacter pylori infection has a body mass index corresponding to normal weight or overweight; determining that a second patient who is positive for Helicobacter pylori infection has a body mass index corresponding to obese or extremely obese; and administering to both the first patient and the second patient, for 14 days, a rifabutin-based triple therapy consisting essentially of rifabutin, amoxicillin and omeprazole or an equivalent amount of a pharmaceutically acceptable salt thereof, wherein, after treatment is complete, there is no substantial difference in the efficacy of the treatment when the treatment is administered to the first patient or the second patient.